Caricamento...
Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia
The advent of novel immunotherapies, such as blinatumomab, inotuzumab, and chimeric antigen receptor (CAR) T cell therapy, has revolutionized the therapeutic landscape in the treatment of relapsed/refractory B cell acute lymphoblastic leukemia, but can be associated with specific toxicities. We revi...
Salvato in:
| Pubblicato in: | Ther Adv Hematol |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6971963/ https://ncbi.nlm.nih.gov/pubmed/32010436 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620719899897 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|